CA2284705A1 - Chemically and thermally stable norastemizole formulations - Google Patents

Chemically and thermally stable norastemizole formulations Download PDF

Info

Publication number
CA2284705A1
CA2284705A1 CA002284705A CA2284705A CA2284705A1 CA 2284705 A1 CA2284705 A1 CA 2284705A1 CA 002284705 A CA002284705 A CA 002284705A CA 2284705 A CA2284705 A CA 2284705A CA 2284705 A1 CA2284705 A1 CA 2284705A1
Authority
CA
Canada
Prior art keywords
norastemizole
pharmaceutically acceptable
lactose
pharmaceutical composition
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002284705A
Other languages
English (en)
French (fr)
Inventor
Martin P. Redmon
Hal T. Butler
Stephen A. Wald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2284705A1 publication Critical patent/CA2284705A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002284705A 1997-03-26 1998-03-25 Chemically and thermally stable norastemizole formulations Abandoned CA2284705A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US82447797A 1997-03-26 1997-03-26
US08/824,477 1997-03-26
US85178697A 1997-05-06 1997-05-06
US08/851,786 1997-05-06
PCT/US1998/005701 WO1998042379A2 (en) 1997-03-26 1998-03-25 Chemically and thermally stable norastemizole formulations

Publications (1)

Publication Number Publication Date
CA2284705A1 true CA2284705A1 (en) 1998-10-01

Family

ID=27124816

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002284705A Abandoned CA2284705A1 (en) 1997-03-26 1998-03-25 Chemically and thermally stable norastemizole formulations

Country Status (13)

Country Link
EP (1) EP1035869A1 (ru)
JP (1) JP2002512614A (ru)
KR (1) KR20010005746A (ru)
CN (1) CN1257431A (ru)
AR (1) AR012187A1 (ru)
BR (1) BR9808428A (ru)
CA (1) CA2284705A1 (ru)
HU (1) HUP0001823A3 (ru)
NO (1) NO994655L (ru)
NZ (3) NZ517472A (ru)
RU (1) RU2214245C2 (ru)
WO (1) WO1998042379A2 (ru)
ZA (1) ZA982562B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20002567A3 (cs) * 2000-07-11 2001-12-12 Léčiva, A.S. Tableta vyrobitelná přímým tabletováním, obsahující aktivní látku kyselinu 4-amino-1-hydroxybutyliden-1,1-bisfosfonovou, a způsob její výroby
EP2201982A1 (en) * 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
ES2736155T3 (es) * 2009-08-24 2019-12-26 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Comprimidos de otilonio por compresión directa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG17993A (en) * 1986-02-03 1991-08-30 Janssen Pharmaceutica Nv Anti-histaminic compositions containing n-heterocyclyl-4-piperidinanines
DE4037426A1 (de) * 1990-11-24 1992-05-27 Kali Chemie Pharma Gmbh Piperidinoalkylbenzoxazin- und -thiazin-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
ES2210957T3 (es) * 1992-09-03 2004-07-01 Sepracor Inc. Composiciones farmaceuticas que contienen norastemizol.
WO1997019074A1 (en) * 1995-11-17 1997-05-29 Hoechst Marion Roussel, Inc. Substituted 4-(1h-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
SK20099A3 (en) * 1996-08-16 2000-08-14 Schering Corp Treatment of upper airway allergic responses with a combination of histamine receptor antagonists

Also Published As

Publication number Publication date
HUP0001823A3 (en) 2002-04-29
NZ527200A (en) 2004-12-24
ZA982562B (en) 1998-10-01
AR012187A1 (es) 2000-09-27
BR9808428A (pt) 2000-05-23
RU2214245C2 (ru) 2003-10-20
NO994655L (no) 1999-11-15
HUP0001823A2 (hu) 2001-04-28
JP2002512614A (ja) 2002-04-23
NZ527201A (en) 2004-12-24
AU735257B2 (en) 2001-07-05
WO1998042379A2 (en) 1998-10-01
NZ517472A (en) 2003-08-29
KR20010005746A (ko) 2001-01-15
WO1998042379A3 (en) 2001-03-01
NO994655D0 (no) 1999-09-24
EP1035869A1 (en) 2000-09-20
AU6868098A (en) 1998-10-20
CN1257431A (zh) 2000-06-21

Similar Documents

Publication Publication Date Title
EP0074584B1 (en) Prolonged-action multiple-layer tablets
JP4435424B2 (ja) 口腔内で速やかに崩壊する錠剤
US20030013740A1 (en) Stable dosage forms of fluoxetine and its enantiomers
US20060127473A1 (en) Compositions and methods for stabilizing active pharmaceutical ingredients
KR20000068914A (ko) 데스카르보에톡시로라타딘의 무 락토오스, 비흡습성 및 무수의 약제학적 조성물
US20080293788A1 (en) Methods and Compositions for the Treatment of Pulmonary Diseases
US20150209311A1 (en) (r,r) formoterol in combination with other pharmacological agents
CA2570386A1 (en) Methods of using albuterol and calcium activated potassium channel openers
JP5572321B2 (ja) 被覆微粒子含有口腔内崩壊錠
US20020173522A1 (en) Pharmaceutical compositions comprising norastemizole
RU2694056C2 (ru) Противотуберкулезная стабильная фармацевтическая композиция в форме диспергируемой таблетки, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления
CA2284705A1 (en) Chemically and thermally stable norastemizole formulations
AU735257C (en) Chemically and thermally stable norastemizole formulations
JPH1067657A (ja) マルチプルユニット型持続性製剤
WO2003075919A1 (fr) Comprime contenant du chlorhydrate de pilsicainide (voie seche)
MXPA99008710A (en) Chemically and thermally stable norastemizole formulations
CZ340699A3 (cs) Farmaceutický prostředek s obsahem norastemizolu
SK19192000A3 (sk) Použitie paroxetínu alebo jeho farmaceuticky prijateľnej soli alebo solvátu na podporu odvykania od fajčenia alebo na zníženie alebo prevenciu relapsu fajčenia
AU2011236040A1 (en) (R,R)-Formoterol in combination with other pharmacological agents
CA2570448A1 (en) Methods and compositions for the treatment of pulmonary diseases

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20060327